Coincidentally, accumulating studies show RAF family, to be precise, CRAF isoform, plays a crucial part in oncogenic KRAS-driven cancers.13–15 More importantly, elimination of CRAF expression in adult mice does not cause significant toxicities, which provides application prospects for CRAF inhibitors as a suitable therapeutic option.13 Intriguingly, pan-RAF inhibitors like LY3009120 were thought effective to overcome the paradoxical activation by inhibiting both B/CRAF monomer and dimmer. The gene discussed is KRAS; the disease is cancer.